KR102832008B1 - Mica/b 유출을 차단하는 항-mica/b 항체 및 사용 방법 - Google Patents

Mica/b 유출을 차단하는 항-mica/b 항체 및 사용 방법 Download PDF

Info

Publication number
KR102832008B1
KR102832008B1 KR1020217005972A KR20217005972A KR102832008B1 KR 102832008 B1 KR102832008 B1 KR 102832008B1 KR 1020217005972 A KR1020217005972 A KR 1020217005972A KR 20217005972 A KR20217005972 A KR 20217005972A KR 102832008 B1 KR102832008 B1 KR 102832008B1
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
seq
delete delete
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217005972A
Other languages
English (en)
Korean (ko)
Other versions
KR20210071947A (ko
Inventor
닐 깁슨
저스틴 채프만
신 두
Original Assignee
컬리난 미카 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 컬리난 미카 코퍼레이션 filed Critical 컬리난 미카 코퍼레이션
Publication of KR20210071947A publication Critical patent/KR20210071947A/ko
Application granted granted Critical
Publication of KR102832008B1 publication Critical patent/KR102832008B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020217005972A 2018-07-31 2019-07-30 Mica/b 유출을 차단하는 항-mica/b 항체 및 사용 방법 Active KR102832008B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862712608P 2018-07-31 2018-07-31
US62/712,608 2018-07-31
PCT/US2019/044234 WO2020028428A2 (en) 2018-07-31 2019-07-30 Anti-mica/b antibodies that block mica/b shedding and methods of use

Publications (2)

Publication Number Publication Date
KR20210071947A KR20210071947A (ko) 2021-06-16
KR102832008B1 true KR102832008B1 (ko) 2025-07-10

Family

ID=69231308

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217005972A Active KR102832008B1 (ko) 2018-07-31 2019-07-30 Mica/b 유출을 차단하는 항-mica/b 항체 및 사용 방법

Country Status (14)

Country Link
US (2) US12065493B2 (https=)
EP (1) EP3830128A4 (https=)
JP (2) JP7370376B2 (https=)
KR (1) KR102832008B1 (https=)
CN (2) CN119930819A (https=)
AU (1) AU2019312565B2 (https=)
CA (1) CA3108022A1 (https=)
IL (1) IL280487B2 (https=)
MX (1) MX2021001254A (https=)
MY (1) MY207765A (https=)
PH (1) PH12021550232A1 (https=)
SG (1) SG11202100981TA (https=)
WO (1) WO2020028428A2 (https=)
ZA (1) ZA202101258B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021001254A (es) 2018-07-31 2021-05-12 Cullinan Mica Corp Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso.
KR20230152783A (ko) 2020-07-07 2023-11-03 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
CN115611982B (zh) * 2021-07-14 2024-05-10 浙江大学 一种抗人MICA/Bα3区的单克隆抗体及其应用
CN114369161B (zh) * 2021-12-28 2023-06-23 合肥天港免疫药物有限公司 Mica抗体及其应用
CN114369162B (zh) * 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
US20250340651A1 (en) * 2022-07-28 2025-11-06 Cullinan Mica Corporation Anti-mica/b antibodies with enhanced effector function and methods of use
CN118027195B (zh) 2023-05-06 2025-07-04 合肥天港免疫药物有限公司 亲和力成熟的mica抗体及其应用
CN119569886A (zh) 2023-09-06 2025-03-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
WO2025085672A1 (en) * 2023-10-17 2025-04-24 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014140904A2 (en) 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
WO2018073648A1 (en) 2016-10-19 2018-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483343A1 (en) 2002-04-22 2003-10-30 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
EP2289534B1 (en) 2004-04-05 2017-08-30 The Regents of The University of California NKG2D antibodies for use in the treatment of rheumatoid arthritis or Crohn's disease
US8716195B2 (en) * 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
EP1857116A1 (en) 2006-05-19 2007-11-21 Novoplant GmbH Antigen binding polypeptides against spike glycoprotein (S2) of bovine coronavirus
CA3011859A1 (en) 2007-04-23 2008-10-30 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by erp5
HUE034044T2 (en) 2011-09-30 2018-01-29 Dana Farber Cancer Inst Inc Therapeutic peptides
AU2013218017B2 (en) * 2012-02-07 2017-12-07 Innate Pharma MICA binding agents
US20150044224A1 (en) 2012-03-02 2015-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Materials and methods for differential treatment of cancer
CA2896058A1 (en) * 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
WO2014140884A2 (en) 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands
WO2014190914A1 (en) 2013-05-30 2014-12-04 The University Of Hong Kong Materials and methods for treatment of liver cancer background of the invention
AU2015264114A1 (en) 2014-05-21 2016-11-03 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti BiP or anti MICA antibodies
EP3430047A1 (en) * 2016-03-15 2019-01-23 Innate Pharma Anti-mica antibodies
WO2017209318A1 (ko) * 2016-05-30 2017-12-07 다이노나(주) 탄산탈수소화 효소에 결합하는 항체 및 이의 용도
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
EP3293271A1 (en) 2016-09-12 2018-03-14 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Marker and target as a diagnostic variable and target for therapy of metastatic cancer
EP3577138A1 (en) 2017-02-06 2019-12-11 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN112566659A (zh) 2018-01-25 2021-03-26 库利南Mica公司 Mica/b抗体和使用方法
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
EP3773676A4 (en) 2018-04-03 2022-05-18 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
MX2021001254A (es) 2018-07-31 2021-05-12 Cullinan Mica Corp Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso.
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014140904A2 (en) 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
WO2018073648A1 (en) 2016-10-19 2018-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use

Also Published As

Publication number Publication date
MY207765A (en) 2025-03-17
US20210253711A1 (en) 2021-08-19
AU2019312565A1 (en) 2021-03-11
JP2021532774A (ja) 2021-12-02
US20250034262A1 (en) 2025-01-30
WO2020028428A3 (en) 2020-05-07
SG11202100981TA (en) 2021-02-25
MX2021001254A (es) 2021-05-12
CN113056484A (zh) 2021-06-29
CA3108022A1 (en) 2020-02-06
US12065493B2 (en) 2024-08-20
CN113056484B (zh) 2025-01-14
IL280487B2 (en) 2025-07-01
BR112021001808A2 (pt) 2021-08-03
JP7370376B2 (ja) 2023-10-27
PH12021550232A1 (en) 2021-12-06
IL280487B1 (en) 2025-03-01
CN119930819A (zh) 2025-05-06
KR20210071947A (ko) 2021-06-16
EP3830128A2 (en) 2021-06-09
EP3830128A4 (en) 2022-08-17
IL280487A (en) 2021-03-25
AU2019312565B2 (en) 2025-09-11
WO2020028428A2 (en) 2020-02-06
JP2024009997A (ja) 2024-01-23
JP7734720B2 (ja) 2025-09-05
ZA202101258B (en) 2025-06-25

Similar Documents

Publication Publication Date Title
KR102832008B1 (ko) Mica/b 유출을 차단하는 항-mica/b 항체 및 사용 방법
KR102731953B1 (ko) Mica/b 항체 및 사용 방법
KR20170068458A (ko) 항-ｎｋｇ2ａ 항체를 사용한 치료 요법
HK1254289A1 (zh) 调控免疫反应的方法及抗体
US20210253713A1 (en) Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
JP2025004078A (ja) ４－１ｂｂ結合タンパク質及びその用途
KR20230019468A (ko) 비고전적 hla-i 및 신생항원을 포함하는 복합체를 표적화하는 항체 및 그의 사용 방법
CN113454114B (zh) 治疗癌症的药物组合
US20220273809A1 (en) Axl antibody-drug conjugates for use in treating cancer
RU2815101C2 (ru) Антитела против mica/b, блокирующие шеддинг mica/b, и способы их применения
RU2821021C2 (ru) Антитела к mica/b и способы применения
CA3089478C (en) Mica/b antibodies and methods of use
TWI790193B (zh) 調控免疫反應之方法及抗體
BR112021001808B1 (pt) Anticorpo monoclonal ou um fragmento de ligação ao antígeno, composição farmacêutica e uso do referido anticorpo monoclonal ou fragmento
WO2024243255A2 (en) Methods of treating cancer with anti-mica/b antibodies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)